The global collaboration gives Lilly access to OmniAb’s specialist ion channel discovery and screening capabilities for an undisclosed therapeutic target and modality.

Funding round will support development of lead targeted alpha therapy ADVC001 in metastatic prostate cancer and expand Lead-212 manufacturing capabilities.

Acquisition gives Lilly late-stage psychedelic pipeline targeting treatment-resistant depression and major psychiatric disorders

Eli Lilly has signed a licensing deal worth up to $1bn with Swedish biotech AlzeCure Pharma for ACD680, a preclinical Alzheimer’s programme targeting amyloid-beta production via gamma-secretase modulation.

Eli Lilly and Ascidian Therapeutics have entered into a multi-year strategic collaboration worth up to $1.9bn, focused on developing RNA exon-editing therapies for undisclosed monogenic kidney diseases.

The company expands into vaccine-led prevention as pharma shifts focus toward long-term disease risk reduction driven by infection-linked chronic outcomes and antimicrobial resistance.

Securing a next-generation JAK2 inhibitor strengthens Lilly’s position in rare blood cancers as pharma accelerates investment in mechanism-driven oncology assets.

New oral weight-loss treatment enters the market as competition with Novo Nordisk’s oral Wegovy accelerates.